Suvemcitug combined with chemotherapy significantly improved PFS and OS in platinum-resistant recurrent ovarian cancer, nearly doubling median PFS and extending median OS. The trial demonstrated ...

For the first time ever, the five-year survival rate for all cancers combined has reached 70 percent. While it's a moment to ...

Results demonstrate a significant survival benefit in the cTMB-H / HRP subset: median OS of almost 6 years (68 months) with Vigil vs. less than 2 years (19 months) for placebo (HR=0.23; p=0.008)7-year ...

Cancer statistics have reached new heights — in good and not-so-good ways. The American Cancer Society (ACS) released its annual report on cancer trends this week, showing for the first time that more ...

In this systematic review and meta-analysis, researchers examined outcomes among advanced ovarian cancer patients who ...

The result is a record 18 million cancer survivors in the US right now, a number expected to grow between 300,000 and 500,000 annually over the next 10 years. In turn, a cancer diagnosis is often no ...

A new clinical study published in the International Journal of Gynecological Cancer reports encouraging results for women ...

The American Cancer Society today released its annual “Cancer Statistics, 2026” and “Cancer Facts & Figures 2026” report — the first national snapshot of this year’s cancer trends. Experts from City ...

Ian C. Cook, MD, discusses the feasibility and benefits of adding bilateral salpingectomy to nongynecologic surgery.

In the PREFER trial, researchers aimed to investigate and assess the safety of strategies for fertility preservation in ...

The combination of ribociclib and letrozole achieved a 30.6% objective response rate and 84% clinical benefit rate in ...

The biotech will explore the potential of BI-1808 plus Keytruda in clear cell and high-grade serous ovarian cancer subtypes.